COVID-19: CTAP and Emergency Use Authorization (EUA) of Hydroxychloroquine and Chloroquine by the FDA

On March 29th the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for donated hydroxychloroquine sulfate and chloroquine phosphate so that it could be used as a possible treatment for COVID-19 or for use in clinical trials.

The EUA requires that fact sheets for each of the medications be available to health care providers as well as patients. Those fact sheets can be found here.

  • Chloroquine Fact Sheets

Fact Sheet for Health Care Providers

Fact Sheet for Patients and Parent/Caregivers

  • Hydroxychloroquine Fact Sheets

Fact Sheet for Health Care Providers

Fact Sheet for Patients and Parent/Caregivers

 

On March 31st the FDA created an emergency program for possible therapies known as the Coronavirus Treatment Acceleration Program (CTAP). The purpose of this program is to expedite potential treatments to patients while also making sure that those treatments aren’t harmful.

 

References:

U.S. FDA: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-30-2020

U.S. FDA: https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap

Flickr: https://www.flickr.com/photos/187587913@N07/49697047852/in/photolist-2iHymUC-2iKaqUG-2iHVRcM-2iGCRgm-2iHGWc2-2iKw951-2iKuwWr-2iKrLH2-2iGSqfk-2iGCvkz-2iJc9J6-2iKo1Jp-2iHkXFy-2iGY61X-2iJXp58-2iGpozX-2iyuhBm-2iGuSHf-2iH3m8P-2iJ5Mr2-2iKfysG-2iJNXm8-2iH7EQu-2iKFkLQ-2iJAEtq-2iGz9yK-2iJz27s-2iJz265-2iJiuTN-2iEnXf2-2iJRooA-2iFf78v-2iH3m8d-2iFTMTZ-2iHNRR6-2iKm6b4-2iENJLE-2iFFsx4-2iy2FH1-2iJyYVJ-2iKJChz-2iJeyF5-2iJ7vhz-2iFk3jW-2iGP8Cc-2iHQk7G-2iJ7vgx-2iGzscq-2iKBSDU-2iGxUaf